Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| TELA Bio, Inc.TELA · Entity 7381 | Director · Chief Executive Officer | February 20, 2026 | February 24, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
TELA Bio, Inc.
Report date February 20, 2026 · Filed February 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 766,110 |
Reported balance
After 2026-02-20 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2026-02-20 · Grant · Acquired 176,000 · Balance 766,110 F1: These restricted stock units ("RSUs") will vest in four equal annual installments beginning on February 20, 2027, subject to the Reporting Person's continuous service through the applicable vesting dates. |
| Common StockSEC Table I · non-derivative | Direct | 753,616 |
Reported balance
After 2026-02-21 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2026-02-21 · Tax withholding · Disposed 12,494 · Balance 753,616 F2: Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of RSUs. |
| Common StockSEC Table I · non-derivative | Direct | 741,985 |
Reported balance
After 2026-02-23 transaction · row 3
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 3 · 2026-02-23 · Tax withholding · Disposed 11,631 · Balance 741,985 F2: Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of RSUs. |
| Common StockSEC Table I · non-derivative | Direct | 586,210 |
Reported balance
After 2026-02-24 transaction · row 4
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 4 · 2026-02-24 · Tax withholding · Disposed 3,900 · Balance 586,210 F2: Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of RSUs. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.72 · Expires 2036-02-20 | Direct | 261,000 |
Reported balance
After 2026-02-20 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-02-20 · Grant · Acquired 261,000 · Balance 261,000 F3: The option vests 25% on February 20, 2027, with the remaining 75% vesting in equal monthly installments on the last day of each of the 36 calendar months immediately following such date, subject to the Reporting Person's continued service through the applicable vesting dates. |
Filing footnotes · ownership attribution and instrument terms
F1: These restricted stock units ("RSUs") will vest in four equal annual installments beginning on February 20, 2027, subject to the Reporting Person's continuous service through the applicable vesting dates.
F2: Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of RSUs.
F3: The option vests 25% on February 20, 2027, with the remaining 75% vesting in equal monthly installments on the last day of each of the 36 calendar months immediately following such date, subject to the Reporting Person's continued service through the applicable vesting dates.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 24, 2026 Filed Feb 24, 2026 20:01 UTC | TELA Bio, Inc. TELA · Entity 7381 | Tax withholdingCommon Stock | 3,900 | $0.79 | $3,062.28 |
DisclosureSEC source: 0001195881-26-000002 · form4-02252026_010251.xml · nonDerivative · entry 4 KOBLISH ANTONY · CIK 0001195881 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 586,210 F2 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of RSUs. Read SEC document |
| February 23, 2026 Filed Feb 24, 2026 20:01 UTC | TELA Bio, Inc. TELA · Entity 7381 | Tax withholdingCommon Stock | 11,631 | $0.77 | $8,909.35 |
DisclosureSEC source: 0001195881-26-000002 · form4-02252026_010251.xml · nonDerivative · entry 3 KOBLISH ANTONY · CIK 0001195881 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 741,985 F2 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of RSUs. Read SEC document |
| February 21, 2026 Filed Feb 24, 2026 20:01 UTC | TELA Bio, Inc. TELA · Entity 7381 | Tax withholdingCommon Stock | 12,494 | $0.72 | $8,963.20 |
DisclosureSEC source: 0001195881-26-000002 · form4-02252026_010251.xml · nonDerivative · entry 2 KOBLISH ANTONY · CIK 0001195881 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 753,616 F2 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of RSUs. Read SEC document |
| February 20, 2026 Filed Feb 24, 2026 20:01 UTC | TELA Bio, Inc. TELA · Entity 7381 | GrantStock Option (Right to Buy) · Derivative | 261,000 | $0.00 Strike: $0.72 | $0.00 |
DisclosureSEC source: 0001195881-26-000002 · form4-02252026_010251.xml · derivative · entry 5 KOBLISH ANTONY · CIK 0001195881 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 261,000 Underlying: Common Stock · 261,000 shares Expires 2036-02-20 F3 · derivative.exercise_date: The option vests 25% on February 20, 2027, with the remaining 75% vesting in equal monthly installments on the last day of each of the 36 calendar months immediately following such date, subject to the Reporting Person's continued service through the applicable vesting dates. Read SEC document |
| February 20, 2026 Filed Feb 24, 2026 20:01 UTC | TELA Bio, Inc. TELA · Entity 7381 | GrantCommon Stock | 176,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001195881-26-000002 · form4-02252026_010251.xml · nonDerivative · entry 1 KOBLISH ANTONY · CIK 0001195881 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 766,110 F1 · shares: These restricted stock units ("RSUs") will vest in four equal annual installments beginning on February 20, 2027, subject to the Reporting Person's continuous service through the applicable vesting dates. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 16:45 UTC | TELA Bio, Inc. TELA · Entity 7381 | Tax withholdingCommon Stock | 384 | $1.22 | $468.48 |
DisclosureSEC source: 0001062993-25-006859 · form4.xml · nonDerivative · entry 1 KOBLISH ANTONY · CIK 0001195881 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 590,110 F1 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of restricted stock units. Read SEC document |
| February 24, 2025 Filed Feb 25, 2025 16:57 UTC | TELA Bio, Inc. TELA · Entity 7381 | Tax withholdingCommon Stock | 5,772 | $2.65 | $15,295.80 |
DisclosureSEC source: 0001062993-25-003497 · form4.xml · nonDerivative · entry 3 KOBLISH ANTONY · CIK 0001195881 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 590,494 F2 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of RSUs. Read SEC document |
| February 23, 2025 Filed Feb 25, 2025 16:57 UTC | TELA Bio, Inc. TELA · Entity 7381 | Tax withholdingCommon Stock | 11,631 | $2.72 | $31,636.32 |
DisclosureSEC source: 0001062993-25-003497 · form4.xml · nonDerivative · entry 2 KOBLISH ANTONY · CIK 0001195881 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 596,266 F2 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of RSUs. Read SEC document |
| February 21, 2025 Filed Feb 25, 2025 16:57 UTC | TELA Bio, Inc. TELA · Entity 7381 | GrantStock Option (Right to Buy) · Derivative | 219,000 | $0.00 Strike: $2.72 | $0.00 |
DisclosureSEC source: 0001062993-25-003497 · form4.xml · derivative · entry 4 KOBLISH ANTONY · CIK 0001195881 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 219,000 Underlying: Common Stock · 219,000 shares Expires 2035-02-21 F3 · derivative.exercise_date: The option vests 25% on February 21, 2026, with the remaining 75% vesting in equal monthly installments on the last day of each of the 36 calendar months immediately following such date, subject to the Reporting Person's continued service through the applicable vesting dates. Read SEC document |
| February 21, 2025 Filed Feb 25, 2025 16:57 UTC | TELA Bio, Inc. TELA · Entity 7381 | GrantCommon Stock | 149,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-003497 · form4.xml · nonDerivative · entry 1 KOBLISH ANTONY · CIK 0001195881 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 607,897 F1 · shares: These restricted stock units ("RSUs") will vest in four equal annual installments beginning on February 21, 2026, subject to the Reporting Person's continuous service through the applicable vesting dates. Read SEC document |
| October 24, 2024 Filed Oct 24, 2024 16:25 UTC | TELA Bio, Inc. TELA · Entity 7381 | PurchaseCommon Stock | 88,888 | $2.25 | $199,998.00 |
DisclosureSEC source: 0001062993-24-017928 · form4.xml · nonDerivative · entry 1 KOBLISH ANTONY · CIK 0001195881 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 458,897 F1 · kind: The shares were purchased in the Issuer's underwritten public offering that closed on October 24, 2024, at the public offering price of $2.25 per share. Read SEC document |
| March 31, 2024 Filed Apr 2, 2024 19:44 UTC | TELA Bio, Inc. TELA · Entity 7381 | Tax withholdingCommon Stock | 385 | $5.67 | $2,182.95 |
DisclosureSEC source: 0001062993-24-007842 · form4.xml · nonDerivative · entry 1 KOBLISH ANTONY · CIK 0001195881 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 370,009 F1 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of restricted stock units. Read SEC document |
| February 24, 2024 Filed Feb 27, 2024 16:36 UTC | TELA Bio, Inc. TELA · Entity 7381 | Tax withholdingCommon Stock | 5,726 | $7.07 | $40,482.82 |
DisclosureSEC source: 0001062993-24-004581 · form4.xml · nonDerivative · entry 3 KOBLISH ANTONY · CIK 0001195881 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 370,394 F2 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of RSUs. Read SEC document |
| February 23, 2024 Filed Feb 27, 2024 16:36 UTC | TELA Bio, Inc. TELA · Entity 7381 | GrantStock Option (Right to Buy) · Derivative | 113,200 | $0.00 Strike: $7.07 | $0.00 |
DisclosureSEC source: 0001062993-24-004581 · form4.xml · derivative · entry 4 KOBLISH ANTONY · CIK 0001195881 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 113,200 Underlying: Common Stock · 113,200 shares Expires 2034-02-23 F3 · derivative.exercise_date: The option vests 25% on February 23, 2025, with the remaining 75% vesting in equal monthly installments on the last day of each of the 36 calendar months immediately following such date, subject to the Reporting Person's continued service through the applicable vesting dates. Read SEC document |
| February 23, 2024 Filed Feb 27, 2024 16:36 UTC | TELA Bio, Inc. TELA · Entity 7381 | Tax withholdingCommon Stock | 5,014 | $7.07 | $35,448.98 |
DisclosureSEC source: 0001062993-24-004581 · form4.xml · nonDerivative · entry 2 KOBLISH ANTONY · CIK 0001195881 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 376,120 F2 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of RSUs. Read SEC document |
| February 23, 2024 Filed Feb 27, 2024 16:36 UTC | TELA Bio, Inc. TELA · Entity 7381 | GrantCommon Stock | 77,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-004581 · form4.xml · nonDerivative · entry 1 KOBLISH ANTONY · CIK 0001195881 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 381,134 F1 · shares: These restricted stock units ("RSUs") will vest in four equal annual installments beginning on February 23, 2025, subject to the Reporting Person's continuous service through the applicable vesting dates. Read SEC document |
| November 14, 2023 Filed Nov 14, 2023 20:01 UTC | TELA Bio, Inc. TELA · Entity 7381 | PurchaseCommon Stock | 11,000 | $4.54 | $49,976.30 |
DisclosureSEC source: 0001062993-23-020847 · form4.xml · nonDerivative · entry 1 KOBLISH ANTONY · CIK 0001195881 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 303,634 F1 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions ranging from $4.49 to $4.55. The Reporting Person undertakes to provide TELA Bio, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| March 31, 2023 Filed Apr 4, 2023 18:03 UTC | TELA Bio, Inc. TELA · Entity 7381 | Tax withholdingCommon Stock | 385 | $10.64 | $4,096.40 |
DisclosureSEC source: 0001062993-23-008668 · form4.xml · nonDerivative · entry 1 KOBLISH ANTONY · CIK 0001195881 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 292,634 F1 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of restricted stock units. Read SEC document |
| February 24, 2023 Filed Feb 27, 2023 19:16 UTC | TELA Bio, Inc. TELA · Entity 7381 | Tax withholdingCommon Stock | 6,034 | $11.03 | $66,555.02 |
DisclosureSEC source: 0001062993-23-005025 · form4.xml · nonDerivative · entry 2 KOBLISH ANTONY · CIK 0001195881 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 293,019 F2 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of RSUs. Read SEC document |
| February 23, 2023 Filed Feb 27, 2023 19:16 UTC | TELA Bio, Inc. TELA · Entity 7381 | GrantStock Option (Right to Buy) · Derivative | 96,100 | $0.00 Strike: $10.50 | $0.00 |
DisclosureSEC source: 0001062993-23-005025 · form4.xml · derivative · entry 3 KOBLISH ANTONY · CIK 0001195881 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,100 Underlying: Common Stock · 96,100 shares Expires 2033-02-23 F3 · derivative.exercise_date: The option vests 25% on February 23, 2024, with the remaining 75% vesting in equal monthly installments on the last day of each of the 36 calendar months immediately following such date, subject to the Reporting Person's continued service through the applicable vesting dates. Read SEC document |
| February 23, 2023 Filed Feb 27, 2023 19:16 UTC | TELA Bio, Inc. TELA · Entity 7381 | GrantCommon Stock | 61,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-005025 · form4.xml · nonDerivative · entry 1 KOBLISH ANTONY · CIK 0001195881 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 299,053 F1 · shares: These restricted stock units ("RSUs") will vest in four equal annual installments beginning on February 23, 2024, subject to the Reporting Person's continuous service through the applicable vesting dates. Read SEC document |
| March 31, 2022 Filed Apr 1, 2022 16:43 UTC | TELA Bio, Inc. TELA · Entity 7381 | Tax withholdingCommon Stock | 384 | $11.63 | $4,465.92 |
DisclosureSEC source: 0001062993-22-009221 · form4.xml · nonDerivative · entry 1 KOBLISH ANTONY · CIK 0001195881 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 237,853 F1 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of restricted stock units. Read SEC document |
| February 24, 2022 Filed Feb 25, 2022 17:11 UTC | TELA Bio, Inc. TELA · Entity 7381 | GrantStock Option (Right to Buy) · Derivative | 79,500 | $0.00 Strike: $11.98 | $0.00 |
DisclosureSEC source: 0001062993-22-005780 · form4.xml · derivative · entry 2 KOBLISH ANTONY · CIK 0001195881 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,500 Underlying: Common Stock · 79,500 shares Expires 2032-02-24 F2 · derivative.exercise_date: The option vests 25% on February 24, 2023, with the remaining 75% vesting in equal monthly installments on the last day of each of the 36 calendar months immediately following such date, subject to the Reporting Person's continued service through the applicable vesting dates. Read SEC document |
| February 24, 2022 Filed Feb 25, 2022 17:11 UTC | TELA Bio, Inc. TELA · Entity 7381 | GrantCommon Stock | 46,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-005780 · form4.xml · nonDerivative · entry 1 KOBLISH ANTONY · CIK 0001195881 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 240,924 F1 · shares: These restricted stock units will vest in four equal annual installments beginning on February 24, 2023, subject to the Reporting Person's continuous service through the applicable vesting dates. Read SEC document |
| February 24, 2022 Filed Feb 28, 2022 16:21 UTC | TELA Bio, Inc. TELA · Entity 7381 | Tax withholdingCommon Stock | 2,687 | $11.98 | $32,190.26 |
DisclosureSEC source: 0001062993-22-005907 · form4.xml · nonDerivative · entry 1 KOBLISH ANTONY · CIK 0001195881 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 238,237 F1 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of restricted stock units. Read SEC document |
| March 31, 2021 Filed Apr 2, 2021 14:43 UTC | TELA Bio, Inc. TELA · Entity 7381 | GrantCommon Stock | 5,439 | $0.00 | $0.00 |
DisclosureSEC source: 0001192482-21-000300 · edgar.xml · nonDerivative · entry 1 KOBLISH ANTONY · CIK 0001195881 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 194,424 F1 · shares: These restricted stock units will vest in four equal annual installments beginning on March 31, 2022, subject to the Reporting Person's continuous service with the Issuer. Read SEC document |
| February 24, 2021 Filed Feb 26, 2021 17:31 UTC | TELA Bio, Inc. TELA · Entity 7381 | GrantCommon Stock (right to buy) · Derivative | 63,600 | $0.00 Strike: $16.99 | $0.00 |
DisclosureSEC source: 0001192482-21-000192 · edgar.xml · derivative · entry 2 KOBLISH ANTONY · CIK 0001195881 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,600 Underlying: Common Stock · 63,600 shares Expires 2031-02-24 F2 · derivative.exercise_date: The option vests 25% on February 24, 2022, with the remaining 75% vesting in equal monthly installments on the last day of each of the 36 calendar months immediately following such date, subject to the Reporting Person's continuous service with the Issuer. Read SEC document |
| February 24, 2021 Filed Feb 26, 2021 17:31 UTC | TELA Bio, Inc. TELA · Entity 7381 | GrantCommon Stock | 34,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001192482-21-000192 · edgar.xml · nonDerivative · entry 1 KOBLISH ANTONY · CIK 0001195881 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 188,985 F1 · shares: These restricted stock units will vest in four equal annual installments beginning on February 24, 2022, subject to the Reporting Person's continuous service with the Issuer. Read SEC document |
| November 13, 2019 Filed Nov 13, 2019 21:09 UTC | TELA Bio, Inc. TELA · Entity 7381 | ConversionWarrant (right to buy) · Derivative | 10,775 | $0.00 Strike: $28.65 | $0.00 |
DisclosureSEC source: 0001192482-19-000434 · edgar.xml · derivative · entry 6 KOBLISH ANTONY · CIK 0001195881 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,775 Underlying: Common Stock · 436 shares Expires 2027-01-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · kind: Warrants exercisable for shares of Series B Preferred Stock automatically converted into warrants exercisable for shares of Common Stock upon the closing of the Issuer's initial public offering. Read SEC document |
| November 13, 2019 Filed Nov 13, 2019 21:09 UTC | TELA Bio, Inc. TELA · Entity 7381 | ConversionWarrant (right to buy) · Derivative | 10,775 | $0.00 Strike: $1.16 | $0.00 |
DisclosureSEC source: 0001192482-19-000434 · edgar.xml · derivative · entry 5 KOBLISH ANTONY · CIK 0001195881 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Series B Preferred Stock · 10,775 shares Expires 2027-01-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · kind: Warrants exercisable for shares of Series B Preferred Stock automatically converted into warrants exercisable for shares of Common Stock upon the closing of the Issuer's initial public offering. Read SEC document |
| November 13, 2019 Filed Nov 13, 2019 21:09 UTC | TELA Bio, Inc. TELA · Entity 7381 | ConversionSeries B Preferred Stock · Derivative | 351,271 | $0.00 | $0.00 |
DisclosureSEC source: 0001192482-19-000434 · edgar.xml · derivative · entry 4 KOBLISH ANTONY · CIK 0001195881 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,225 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Shares of Series B Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date. F3 · derivative.exercise_date: Shares of Series B Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date. F3 · derivative.expiration_date: Shares of Series B Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date. Read SEC document |
| November 13, 2019 Filed Nov 13, 2019 21:09 UTC | TELA Bio, Inc. TELA · Entity 7381 | ConversionSeries A Preferred Stock · Derivative | 179,685 | $0.00 | $0.00 |
DisclosureSEC source: 0001192482-19-000434 · edgar.xml · derivative · entry 3 KOBLISH ANTONY · CIK 0001195881 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,277 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Shares of Series A Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date. F1 · derivative.exercise_date: Shares of Series A Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date. F1 · derivative.expiration_date: Shares of Series A Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date. F4 · derivative.underlying_shares: Reflects 1-for-24.69 reverse stock split which became effective on October 28, 2019. Read SEC document |
| November 13, 2019 Filed Nov 13, 2019 21:09 UTC | TELA Bio, Inc. TELA · Entity 7381 | ConversionCommon Stock | 14,225 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001192482-19-000434 · edgar.xml · nonDerivative · entry 2 KOBLISH ANTONY · CIK 0001195881 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,085 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Shares of Series B Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date. Read SEC document |
| November 13, 2019 Filed Nov 13, 2019 21:09 UTC | TELA Bio, Inc. TELA · Entity 7381 | ConversionCommon Stock | 7,277 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001192482-19-000434 · edgar.xml · nonDerivative · entry 1 KOBLISH ANTONY · CIK 0001195881 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,860 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Shares of Series A Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date. F2 · balance_after: Reflects 16,273 shares of common stock received by the reporting person as a payment-in-kind dividend on Series A Preferred Stock and Series B Preferred Stock exempt from reporting under Rule 16a-9(a). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.